Literature DB >> 20869831

Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy.

Michael D Wiese1, Noel W Davies, Tim K Chataway, Robert W Milne, Simon G A Brown, Robert J Heddle.   

Abstract

Allergy to Myrmecia pilosula (Jack Jumper Ant) venom is common in Australia, affecting ∼2.7% of some communities. Venom immunotherapy is a highly effective treatment, but for the venom to be widely distributed for clinical use, the stability and shelf-life of formulated Jack Jumper Ant venom must be demonstrated. HPLC-UV, ELISA Inhibition, SDS-PAGE and SDS-PAGE Immunoblot were used to assess venom stability under conditions of varying temperature, pH and in the presence of various stabilising agents. Optimal stability occurred between pH 8 and 10, however the presence of benzyl alcohol within this pH range resulted in a cloudy appearance within 3 days, so a pH of 6 was used. Increasing polysorbate 80 concentrations accelerated the degradation of allergenic peptides in 100 μg/mL venom, but improved stability at concentrations of 1 μg/mL or less. Sucrose reduced degradation of allergens Myr p 1 and Myr p 3, whilst glycerol was destabilizing. In the presence of 22% sucrose, 1.1mg/mL Jack Jumper Ant venom was stable at -18 °C and 4 °C for 12 months; following dilution to 100 μg/mL with 0.9% sodium chloride, 10mM phosphate (pH 6), 0.05% polysorbate 80 and 0.9% benzyl alcohol (giving 2% sucrose), venom was stable for 7 days when stored at 4 °C. Concentrated Jack Jumper Ant venom can be stored in 22% sucrose for 12 months, and after dilution to 100 μg/mL for clinical use, it should be discarded after 7 days.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20869831     DOI: 10.1016/j.jpba.2010.08.024

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Bioactivity of Samsum ant (Pachycondyla sennaarensis) venom against lipopolysaccharides through antioxidant and upregulation of Akt1 signaling in rats.

Authors:  Hossam Ebaid; Mohamed Al-Khalifa; Ahmed M Isa; Saad Gadoa
Journal:  Lipids Health Dis       Date:  2012-07-23       Impact factor: 3.876

2.  Worldwide perspectives on venom allergy.

Authors:  Peter Korošec; Thilo Jakob; Harfi Harb; Robert Heddle; Sarah Karabus; Ricardo de Lima Zollner; Julij Selb; Bernard Yu-Hor Thong; Fares Zaitoun; David B K Golden; Michael Levin
Journal:  World Allergy Organ J       Date:  2019-10-24       Impact factor: 4.084

3.  Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy.

Authors:  Troy Wanandy; Yoshikazu Honda-Okubo; Noel W Davies; Hayley E Rose; Robert J Heddle; Simon G A Brown; Richard J Woodman; Nikolai Petrovsky; Michael D Wiese
Journal:  J Pharm Biomed Anal       Date:  2019-04-09       Impact factor: 3.935

4.  Thymoquinone ameliorates Pachycondyla sennaarensis venom-induced acute toxic shock in male rats.

Authors:  Ibrahim M Alhazza; Hossam Ebaid; Bahaa Abdel-Salam; Jameel H Al-Tamimi; Iftekhar Hassan; Ahmed M Rady; Ashraf M A Mashaly
Journal:  BMC Pharmacol Toxicol       Date:  2019-12-17       Impact factor: 2.483

Review 5.  Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management.

Authors:  Troy Wanandy; Emily Mulcahy; Wun Yee Lau; Simon G A Brown; Michael D Wiese
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-01       Impact factor: 8.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.